33.37
전일 마감가:
$32.09
열려 있는:
$31.97
하루 거래량:
1.28M
Relative Volume:
1.31
시가총액:
$2.47B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-12.18
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
+5.07%
1개월 성능:
+10.97%
6개월 성능:
-16.93%
1년 성능:
-8.73%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
XENE
Xenon Pharmaceuticals Inc
|
33.37 | 2.47B | 13.17M | -199.06M | -156.53M | -2.74 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-07 | 개시 | Chardan Capital Markets | Buy |
2025-02-11 | 개시 | Deutsche Bank | Buy |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-10-01 | 개시 | H.C. Wainwright | Buy |
2024-01-04 | 개시 | Citigroup | Buy |
2023-12-08 | 개시 | Robert W. Baird | Outperform |
2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
2022-12-14 | 개시 | Goldman | Buy |
2022-12-12 | 개시 | Cowen | Outperform |
2022-11-28 | 개시 | Wells Fargo | Overweight |
2022-10-19 | 개시 | Raymond James | Outperform |
2022-08-29 | 개시 | BofA Securities | Buy |
2022-07-21 | 개시 | JP Morgan | Overweight |
2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
2020-10-02 | 개시 | SVB Leerink | Outperform |
2020-07-21 | 개시 | Needham | Buy |
2020-06-01 | 재개 | Jefferies | Buy |
2020-03-25 | 개시 | Wedbush | Outperform |
2020-01-08 | 개시 | William Blair | Outperform |
2019-09-20 | 개시 | Guggenheim | Buy |
2018-08-08 | 재확인 | Stifel | Buy |
2017-03-13 | 개시 | Jefferies | Buy |
2016-10-21 | 개시 | Stifel | Buy |
2016-09-26 | 개시 | Guggenheim | Buy |
2016-04-14 | 재확인 | Jefferies | Buy |
2015-10-30 | 재개 | Jefferies | Buy |
2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk - MarketScreener
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Xenon Pharmaceuticals at Goldman Sachs Conference: Strategic Clinical Advances By Investing.com - Investing.com Canada
Transcript : Xenon Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 03 - MarketScreener
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Squarepoint Ops LLC - Defense World
xenon pharmaceuticals reports shareholder voting results By Investing.com - Investing.com South Africa
xenon pharmaceuticals reports shareholder voting results - Investing.com
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon to Present at the Goldman Sachs 46th Annual Global Healthc - GuruFocus
Xenon Pharmaceuticals to Present at Global Healthcare Conference - TipRanks
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | XENE Stock News - GuruFocus
Xenon CEO to Update Investors on Breakthrough Epilepsy Drug at Goldman Sachs Healthcare Conference - Stock Titan
Stock Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Analyzing Xenon Pharmaceuticals (NASDAQ:XENE) and Inhibitor Therapeutics (OTCMKTS:INTI) - Defense World
Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Lis - GuruFocus
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Awards $1.5M in Stock Options to 7 New Hires Under Nasdaq Rule - Stock Titan
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE - Defense World
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Xenon Pharmaceuticals at RBC Capital Markets: Strategic Insights on Ezetucalmer - Investing.com India
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India
Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World
XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World
Wedbush Equities Analysts Cut Earnings Estimates for XENE - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World
HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World
How To Trade (XENE) - news.stocktradersdaily.com
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World
Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World
Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
GANNON STEVEN | Director |
May 14 '25 |
Option Exercise |
12.57 |
5,144 |
64,660 |
7,144 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Option Exercise |
17.76 |
22,468 |
399,032 |
53,770 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
자본화:
|
볼륨(24시간):